BTNL8 and cranioectodermal dysplasia: Interestingly, 10.9% (5/46) of controls were homozygous for the BTNL8*BTNL3 deletion compared to only 4.2% (2/48) of CeD patients, but this did not reach statistical significance (Table A8, Figure A7, Fisher’s exact test, p = 0.2144).